A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML)
Clinical trial NCT02997202 · COMPLETED
Trial details
- NCT number
- NCT02997202
- Sponsor
- Astellas Pharma Global Development, Inc.
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2017-08-16
- Primary completion
- 2023-01-07
- Enrollment
- 356
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.